Clinical Trials
Case Study: How Altasciences Launched a Phase I Study 70% Faster Than the Industry Standard
Clinical trial start-up is a critical phase that carries many risks of delay, that can adversely impact the study timelines and budget. Altasciences was able to achieve an expedited project launch from the typical 12-week start-up process to just 3.5 weeks for a client by aligning our internal team on all objectives, engaging in open dialogue with the sponsor, and optimizing project management by assigning two project leads in two different time zones.
Case Study—Driving Simulator Assessment
How Combined CDMO and Clinical Teams Accelerate Drug Development
Streamlined Processes. Faster Approval.
In this new video, we share how our integrated teams’ combined expertise in clinical trials and manufacturing simplify the drug development process, empowering you to bring innovative therapies to market faster and, ultimately, improve patient outcomes.
Watch now to learn how our cohesive approach minimizes delays, reduces costs, and enhances collaboration.
Looking for drug development and manufacturing services? Speak with one of our experts today.
Related resources that may interest you:
- Webpage: Pharmaceutical Contract Manufacturing Services
- eBook: Advantages of Conducting Early-Phase Clinical Research in Canada
- Webinar: Overcoming Challenges in Manufacturing for Clinical Trials
Hot off the Press! - November 2024
Altasciences Supports Metsera in Their Early Stage Clinical Trials for Obesity
Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company, with nonclinical and early-stage clinical trials. This support includes a recent Phase I/II trial of MET-097i: an ultra-long-acting injectable amylin analog and fully biased GLP-1 receptor agonist.
In a trial conducted at our clinic, Metsera reported positive topline results. This study enabled Metsera to initiate a randomized 16-week Phase II trial of MET-097i, which could offer potential new treatment options for those affected by obesity. We also further supported Metsera with our proactive drug development solution, providing nonclinical, bioanalysis, CRO, and program management services for several other therapeutic candidates.
Altasciences Upholds Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services
A trusted drug development research partner for over 30 years, Altasciences remains committed to providing world-class bioanalytical services in support of the preclinical and clinical studies conducted at our cutting-edge facilities, as well as extensive standalone solutions to meet your diverse needs.
Our flexible bioanalytical services from discovery to Phase IV empower clients across every phase of research.
Let's Promote Your Project!
Interested in a custom press release, written by our experts, to feature the great research we do together? Email us to get started!
You may also be interested in:
- The Altascientist Issue No.42: Managing the Complexities of Glucagon-Like Peptide-1 Receptor Agonist Drug Development
- The Altascientist Issue No.41: Immunomodulation Assessments for Clinical Trials: Sophisticated Bioanalytical Approaches to Support Complex Modalities
- Case Study: GLP-1 RA: Overcoming Known Pharmacological Effects
- Case Study: GLP-1 RA: Rapid Clinical Phase I Study Execution
- Blog: 4 Essential Topics to Cover in Your First CRO Meeting
- Press Releases: View More
[On-Demand Webinar] The Future of GLP-1 Drugs
As GLP-1 drugs reshape the market, understanding their potential risks, applications, and economic effects is crucial for professionals in the pharmaceutical and healthcare industries.
Join Altasciences’ webinar to discover future trends and potential breakthroughs.
Speak with one of our experts to discuss your drug development program.
You may also be interested in these resources
- Scientific Journals: Managing the Complexities of GLP-1 Drug Development
- Fact Sheet: Metabolic Disorders Clinical Trials
- Case Study: Randomized Cross Over Efficacy Study Metabolic Disorder
GLP-1 RA: Rapid Clinical Phase I Study Execution
Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity
Laval, Québec, November 21, 2024—Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, on its nonclinical and early-stage clinical trials. This support includes a recent Phase I/II trial of MET-097i, an ultra-long-acting injectable, fully biased GLP-1 receptor agonist.
In September, Metsera reported positive topline results from the clinical trial conducted at Altasciences’ facility, in which MET-097i demonstrated a 7.5% reduction in body weight from baseline at day 36 (one week after the final dose) and a 380-hour half-life. This work enabled Metsera to recently initiate a randomized 16-week Phase II trial of MET-097i.
In addition to clinical conduct, Altasciences supported Metsera with its proactive drug development solution, including nonclinical, bioanalysis, CRO and program management services for several additional therapeutic candidates. Over the past six months, Altasciences has completed nonclinical work for MET-233i, an ultra-long-acting injectable amylin analog, as well as MET-002, an oral GLP-1 receptor agonist peptide, which has proven instrumental in allowing Metsera to begin clinical trials for both programs this year.
"Congratulations to Metsera on reaching this significant milestone in the development of MET-097i," said Ingrid Holmes, Vice President of Global Clinical Operations at Altasciences. "Metsera is a highly valued partner of Altasciences, and we are proud to have contributed to this program aimed at helping individuals struggling with obesity-related illnesses."
Obesity impacts millions of people worldwide and is a driver of serious health risks, including type 2 diabetes, heart disease, and certain cancers. Innovative treatments, like MET-097i, could offer potential new treatment options for those affected by this complex condition.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
Julie-Ann Cabana
Altasciences
jcabana@altasciences.com
Altasciences’ Commitment to Bioanalytical Excellence
Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services
We have been your trusted drug development research partner for over 30 years. We are committed to providing world-class bioanalytical services in support of the preclinical and clinical studies conducted at our cutting-edge facilities, as well as extensive standalone solutions to meet your diverse needs. Our flexible bioanalytical services from discovery to Phase IV empower our clients across every phase of research.
We recently launched the Unveiling the Invisible video campaign to showcase how our bioanalytical solutions provide critical insights that unveil the invisible and drive the creation of your innovative therapies.
RELATED RESOURCES
Our bioanalytical team excels in comprehensive bioanalytical services, including assay and method development, molecular biology, mass spectrometry, ligand binding assays, immunogenicity testing, biomarker analysis, flow cytometry services, and more, to support your journey from discovery through Phase IV.
Below are some resources that highlight our extensive knowledge, and wealth of bioanalytical experience.
- The Altascientist Issue 41: Immunomodulation Assessments for Clinical Trials—Sophisticated Bioanalytical Approaches to Support Complex Modalities
- eBook: Key Considerations for Nonclinical AAV Gene Therapy Development
- eBook: Key Biomarkers of Immunomodulation
- Scientific Research Article: A Novel Hybridization LC-MS/MS Methodology for Quantification of siRNA
- Scientific Research Article: A Validated Capillary Microsampling LC-MS Method for Quantification of ASOs in Mouse Serum
- Scientific Research Article: Microsampling in Pediatric Studies
Discover the Dynamic Landscape of GLP-1 Drug Development
In this issue of The Altascientist, we explore the current and future development of GLP-1 receptor agonists (GLP-1 RAs), and the complexities involved in the early phases.
Topics covered include preclinical models, bioanalytical assays, clinical study design, manufacturing, and the expanding applications of GLP-1 drugs in treating various health conditions. Exclusive case studies are also presented.
Questions about your drug development program? Speak with one of our experts.
Related resources that may interest you:
Going Above and Beyond to Exceed Your Expectations
In this new video, our clinical and manufacturing experts share how their teams collaborate and tailor solutions to meet your unique needs. They highlight real examples of going above and beyond by implementing innovative strategies to ensure your projects stay on track.
Looking for a more seamless drug development and manufacturing experience? Speak with one of our experts today.
Related resources that may interest you:
- Video: Nine Strategic Locations to Accelerate Study Timelines
- eBook: Maximizing Drug Formulation for First-in-Human Trials
- Webpage: Pharmaceutical Contract Manufacturing Services
- Podcast: Key Considerations as You Move From Discovery to Preclinical to Clinical